OncoSec Medical Inc. (OTCQB: ONCS),
a company developing its advanced-stage ImmunoPulse DNA-based
immunotherapy to treat solid tumors, today announced that Punit Dhillon,
President and CEO, will present a corporate overview of the company at
the 24th Annual Wall Street Analyst Forum Institutional Investor
Conference at the University Club in New York, New York on Monday, March
3rd at 12:05 p.m. (EST).
At the time of the presentation, a live webcast of OncoSec’s
presentation will be available at the following link: http://www.visualwebcaster.com/event.asp?id=98095
OncoSec recommends registering at least 10 minutes prior to the start of
the presentation to ensure timely access. Participants will require
Windows Media Player (a free download is available from the presentation
link) in order to participate. After the presentation, an archived
version of the webcast will be available on OncoSec’s web page at http://www.oncosec.com under
the “Events” tab.
About the Wall Street Analyst Forum Institutional Investor Conference
Since 1989, the Wall Street Analyst Forum has conducted over 80
multiday/multitrack analyst conferences in Boston, New York, and London;
in which over 2500 different NYSE/NASDAQ/AMEX/OTC companies have
presented, and over 2000 different institutions have attended. Analysts
and portfolio managers from the vast majority of money management firms
attend its conferences either in person or via webcast, and past
presenters have included such companies as General Electric, Pfizer,
Microsoft Corp, and Mattel. In 1998, WSAF received extensive coverage in
the financial press for conducting the first live webcast of individual
corporate meetings from an investor conference. The 24th
Annual Institutional Investor Conference will take place March 3-4, 2014
at the University Club in New York City.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its
advanced-stage ImmunoPulse immunotherapy to treat solid tumors. OncoSec
Medical's core technology leverages a proprietary electroporation
platform to enhance the local delivery and uptake of IL-12 and other
DNA-based immunocytokines. Clinical studies of ImmunoPulse have
demonstrated positive safety and preliminary efficacy in the treatment
of various skin cancers, as well as its potential to initiate a systemic
immune response without the toxicities associated with other systemic
treatments. OncoSec's clinical programs currently include three Phase 2
clinical trials targeting metastatic melanoma, Merkel cell carcinoma and
cutaneous T-cell lymphoma. As the company continues to evaluate
ImmunoPulse in these indications, it is also investigating additional
indications as well as efficacious combination approaches. For more
information, please visit www.oncosec.com.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such “forward-looking statements.” Forward-looking statements
are based on management’s current preliminary expectations and are
subject to risks and uncertainties, which may cause our results to
differ materially and adversely from the statements contained herein.
Some of the potential risks and uncertainties that could cause actual
results to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or commercialize new
products, uncertainties inherent in pre-clinical studies and clinical
trials, unexpected new data, safety and technical issues, competition,
and market conditions. These and additional risks and uncertainties are
more fully described in OncoSec Medical’s filings with the Securities
and Exchange Commission. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they are
made. OncoSec Medical disclaims any obligation to update any
forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.
Copyright Business Wire 2014